number of patients with decrease of blisters' number of at least 20% after 3 months of treatment by oral erythromycin at 3 months of treatment [clinicaltrials_resource:db41fee07b6bf760b57bedbea73340e5]
Principal end point is evaluated at inclusion and after one month of treatment, 3 months of treatment and 2 months after the end of the treatment
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
number of patients with decrease of blisters' number of at least 20% after 3 months of treatment by oral erythromycin at 3 months of treatment [clinicaltrials_resource:db41fee07b6bf760b57bedbea73340e5]
Principal end point is evaluated at inclusion and after one month of treatment, 3 months of treatment and 2 months after the end of the treatment
Bio2RDF identifier
db41fee07b6bf760b57bedbea73340e5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:db41fee07b6bf760b57bedbea73340e5
measure [clinicaltrials_vocabulary:measure]
number of patients with decrea ...... treatment by oral erythromycin
time frame [clinicaltrials_vocabulary:time-frame]
at 3 months of treatment
description
Principal end point is evaluat ...... after the end of the treatment
identifier
clinicaltrials_resource:db41fee07b6bf760b57bedbea73340e5
title
number of patients with decrea ...... mycin at 3 months of treatment
@en
type
label
number of patients with decrea ...... 1fee07b6bf760b57bedbea73340e5]
@en